Gain Therapeutics, Inc.

Name: Gain Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

GANXNasdaqCIK 1819411HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2023

Operating income−$4.7m, Q2 FY2026

Net income−$4.7m, Q2 FY2026

Gain Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	2,367	2,374	2,507	4,438	2,622	1,225	2,257	2,759	2,850	2,347	2,763	2,138
Operating income	$k	(4,885)	(4,407)	(4,378)	(8,183)	(4,459)	(3,331)	(4,369)	(5,090)	(4,786)	(4,466)	(5,354)	(4,682)
Income tax	$k	21.5	14.5	19.9	1.2	11.0	505	101	141	549	70.1	183	104
Net income	$k	(4,718)	(4,724)	(4,014)	(8,143)	(4,486)	(3,768)	(4,530)	(5,809)	(5,284)	(4,538)	(5,609)	(4,676)
Diluted EPS	$ per share	(0.37)	not reported	(0.22)	(0.42)	(0.17)	not reported	(0.16)	(0.19)	(0.15)	not reported	(0.13)	(0.11)
Basic EPS	$ per share	(0.37)	not reported	(0.22)	(0.42)	(0.17)	not reported	(0.16)	(0.19)	(0.15)	not reported	(0.13)	(0.11)

Balance sheet

Cash and equivalents$13.1m, Q2 FY2026

Long-term debt$220.1k, Q2 FY2026

Shareholders' equity$11.3m, Q2 FY2026

Gain Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	4.3	11.8	10.6	16.9	12.0	10.4	9.1	6.7	8.8	20.8	16.5	13.1
Current assets	$m	13.2	17.8	13.9	18.5	13.7	11.6	11.2	9.3	10.5	22.2	18.2	15.0
Total assets	$m	14.1	18.6	14.6	19.2	14.4	12.1	11.6	9.8	11.0	22.8	18.7	15.4
Current liabilities	$m	5.8	4.9	5.0	6.5	4.6	3.9	5.0	5.2	4.2	3.4	3.9	3.4
Total liabilities	$m	6.8	6.0	5.9	7.4	5.5	4.8	5.8	6.1	5.1	4.3	4.7	4.1
Long-term debt	$m	0.4	0.4	0.4	0.4	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2
Current portion of debt	$m	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Shareholders' equity	$m	7.3	12.6	8.6	11.8	8.9	7.3	5.8	3.7	5.9	18.6	14.0	11.3

Cash flow

Operating cash flow−$4.7m, Q2 FY2026

Capital expenditure$945, Q4 FY2024

Gain Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,967)	(5,660)	(3,587)	(5,756)	(6,076)	(3,455)	(3,822)	(5,099)	(4,926)	(4,618)	(4,728)	(4,680)
Capital expenditure	$k	0.7	0.0	not reported	not reported	0.0	0.9	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)42.88m, Q2 FY2026

Gain Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	11.9	11.9	12.4	12.7	18.0	19.2	26.5	28.7	30.3	35.0	42.2	42.9

Shares outstanding: 43.64m at Jul 31, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.